Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT1 | P17948 | 17/20 | 0.63 |
| ▸ | KDR | P35968 | 17/20 | 0.63 |
| ▸ | FGFR1 | P11362 | 16/20 | 0.63 |
| ▸ | EGFR | P00533 | 13/20 | 0.63 |
| ▸ | FLT4 | P35916 | 12/20 | 0.63 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.61 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.58 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5451140 | 0.99 | FLT1 (0.63) | FLT1KDRFGFR1EGFRFLT4 | |
| SCHEMBL6959851 | 0.93 | KDR (0.68) | FLT1KDRFGFR1EGFRFLT4 | |
| SCHEMBL5450355 | 0.91 | FLT1 (0.64) | FLT1KDRFGFR1EGFRFLT4 | |
| Hydrochloric Acid SCHEMBL5453219 | 0.90 | FLT1 (0.65) | FLT1KDRFGFR1EGFRFLT4 | |
| SCHEMBL5456122 | 0.89 | FLT1 (0.72) | FLT1KDRFGFR1EGFRFLT4 | |
| SCHEMBL5755914 | 0.89 | FLT1 (0.75) | FLT1KDRFGFR1EGFRFLT4 | |
| SCHEMBL14564686 | 0.89 | FLT1 (0.75) | FLT1KDRFGFR1EGFRFLT4 | |
| Hydrochloric Acid SCHEMBL5446837 | 0.88 | FLT1 (0.71) | FLT1KDRFGFR1EGFRFLT4 | |
| SCHEMBL5465089 | 0.88 | FLT1 (0.73) | FLT1KDRFGFR1EGFRFLT4 | |
| SCHEMBL5450340 | 0.88 | FLT1 (0.73) | FLT1KDRFGFR1EGFRFLT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7160889-B2 | Quinazoline compounds | ASTRAZENECA AB (SE) | 2007-01-09 | — | — | US | claimed |
| EP-1274692-B1 | QUINAZOLINE COMPOUNDS | ASTRAZENECA AB (SE) | 2006-08-02 | — | — | EP | claimed |
| US-20030191308-A1 | Quinazoline compounds | ASTRAZENECA AB (SE) | 2003-10-09 | — | — | US | claimed |
| US-20070066633-A1 | Quinazoline compounds | ASTRAZENECA AB | 2007-03-22 | — | — | US | disclosed |
| US-7160889-B2 | Quinazoline compounds | ASTRAZENECA AB (SE) | 2007-01-09 | — | — | US | disclosed |
| EP-1274692-B1 | QUINAZOLINE COMPOUNDS | ASTRAZENECA AB (SE) | 2006-08-02 | — | — | EP | disclosed |
| US-20030191308-A1 | Quinazoline compounds | ASTRAZENECA AB (SE) | 2003-10-09 | — | — | US | disclosed |
| EP-1274692-A1 | QUINAZOLINE COMPOUNDS | AstraZeneca AB (SE) | 2003-01-15 | — | — | EP | disclosed |
| WO-2001077085-A1 | QUINAZOLINE COMPOUNDS | ASTRAZENECA AB (SE) | 2001-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191308-A1 | Quinazoline compounds | CNR1, CBR1, CCR7 | FLT1 11/4885KDR 85/4885FGFR1 911/4885 |
| US-20070066633-A1 | Quinazoline compounds | CCR7, CNR1, CBR3 | FLT1 21/4885KDR 93/4885FGFR1 712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.